Williamson Ian
The University of Southampton, Southampton, UK.
BMJ Clin Evid. 2011 Jan 12;2011:0502.
Up to 80% of children have been affected by otitis media with effusion (OME) by the age of 4 years, but prevalence declines beyond 6 years of age. Non-purulent middle-ear infections can occur in children or adults after upper respiratory tract infection or acute otitis media. Half or more of cases resolve within 3 months and 95% within 1 year, but complications such as tympanic membrane perforation, tympanosclerosis, otorrhoea, and cholesteatoma can occur.
We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent otitis media with effusion in children? What are the effects of pharmacological, mechanical, and surgical interventions to treat otitis media with effusion in children? We searched: Medline, Embase, The Cochrane Library, and other important databases up to March 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
We found one systematic review and one RCT that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
In this systematic review, we present information relating to the effectiveness and safety of the following interventions: adenoidectomy, antibiotics, antihistamines, autoinflation, bottle feeding, decongestants, exposure to other children, intranasal corticosteroids, mucolytics, oral corticosteroids, passive smoking, and ventilation tubes.
到4岁时,高达80%的儿童曾患分泌性中耳炎(OME),但6岁以后患病率下降。非化脓性中耳感染可发生于儿童或成人上呼吸道感染或急性中耳炎之后。半数或更多病例在3个月内痊愈,95%在1年内痊愈,但可出现诸如鼓膜穿孔、鼓室硬化、耳漏和胆脂瘤等并发症。
我们进行了一项系统评价,旨在回答以下临床问题:预防儿童分泌性中耳炎的干预措施有哪些效果?治疗儿童分泌性中耳炎的药物、机械和手术干预措施有哪些效果?我们检索了:截至2010年3月的Medline、Embase、Cochrane图书馆及其他重要数据库(Clinical Evidence评价定期更新;请查阅我们的网站获取本评价的最新版本)。我们纳入了来自美国食品药品监督管理局(FDA)和英国药品和医疗产品监管局(MHRA)等相关组织的危害警示。
我们发现一项系统评价和一项随机对照试验符合我们的纳入标准。我们对干预措施的证据质量进行了GRADE评估。
在本系统评价中,我们提供了以下干预措施有效性和安全性的相关信息:腺样体切除术、抗生素、抗组胺药、自行鼓气、奶瓶喂养、减充血剂、接触其他儿童、鼻内用糖皮质激素、黏液溶解剂、口服糖皮质激素、被动吸烟和通气管。